Compare Genworth Financial Inc Common Stock (GNW) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Genworth Financial Inc Common Stock vs GeneDx Holdings Corp — how do they compare? Genworth Financial Inc Common Stock trades at $8.82 (market cap $3.36B), while GeneDx Holdings Corp trades at $68.8 (market cap $1.94B). The key difference: Genworth Financial Inc Common Stock is the larger of the two by market cap, and GeneDx Holdings Corp is more actively traded (524,385 versus 3,333,156). Which is the better fit depends on your goals — on Pluang, investors hold Genworth Financial Inc Common Stock for 0 Days and GeneDx Holdings Corp for 20 Days on average.
| GNW | WGS | |
|---|---|---|
Market Cap | $3.36B | $1.94B |
Volume | 3,333,156 | 524,385 |
Sector | Financials | Health |
52-Week High | $10.60 | $167.51 |
52-Week Low | $7.94 | $34.51 |
Typical Hold Time | 0 Days | 20 Days |
Enterprise Value | $2.87B | $1.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Genworth Financial (GNW) trades at $8.89, down 1.77% today, with neutral technical signals and mixed fundamental performance. The company maintains stable revenue around $7.1-7.2B but faces margin pressure, with net income declining from $223M to $212M year-over-year. Recent Q2 2026 earnings beat expectations at $0.29 EPS, while the company expanded its share repurchase program by $500M in September 2026.
GNW presents value characteristics with low P/B (0.38) and P/S (0.49) ratios, but weak profitability metrics (ROE 2.42%) and analyst caution (70.59% hold rating) suggest limited near-term catalysts. Key risks include legacy insurance liabilities and competitive pressures, while the upcoming Q3 earnings on November 4 could provide directional clarity.
GeneDx (WGS) trades at $64.96, up 1.79% today, showing mixed signals with bearish technical indicators but strong analyst support. The company reported Q2 2026 revenue of $114.4 million, beating expectations with record testing volumes, though profitability remains challenged with negative net margins. Recent news highlights product innovations and leadership recognition, while institutional interest grows with Dimensional Fund Advisors increasing its position by 143.4% in Q1 2026.
The stock presents a high-risk opportunity with 91% analyst buy ratings and an $81 consensus target offering 25% upside. However, significant fundamental challenges include negative profitability, high valuation multiples, and cash flow volatility. Investors should weigh strong growth potential in genomic testing against execution risks and competitive pressures in the healthcare technology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Genworth Financial Inc Common Stock
Genworth Financial, Inc. is a holding company that provides products and services related to aging and long-term care planning, and is the parent company of publicly traded mortgage insurer Enact Holdings, Inc.
Read more on GNW →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
